Novo Nordisk A/S

Copenhagen Stock Exchange:NOVO-B.CO

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Denmark

Market Cap

USD 300.06 B

Share Price

USD 68.56

Avg Daily Volume

5,846,065

Change (1 day)

1.71%

Change (1 year)

-52.27%

Change (YTD)

-21.04%

Novo Nordisk A/S Share Price Year-To-Date (YTD) return on June 27, 2025: -21.04%

Novo Nordisk A/S Share Price Year-To-Date (YTD) return is -21.04% on June 27, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Novo Nordisk A/S 52-week low Share Price is USD 144.49 on June 27, 2025, which is 110.76% above the current Share Price.
Novo Nordisk A/S 52-week low Share Price is USD 59.10 on June 27, 2025, which is -13.80% below the current Share Price.
Novo Nordisk A/S average Share Price for the last 52 weeks is USD 99.30.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Copenhagen Stock Exchange: NOVO-B.CO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 6, 2001
Location	Denmark
Headquarters	Novo Alle 1
Employees	77,406
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.